ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • ROS1 fusion

carboplatin • pemetrexed • Yidafan (ivonescimab)

Single-nucleus multi-omics delineates distinct epigenetic programs associated with tumor progression in lung adenocarcinoma. (PubMed, Clin Epigenetics)

These findings indicate patient-specific patterns of tumor evolution in LUAD, with one case showing a progressive AT2-to-tumor transition and another driven by ROS1 fusion-mediated oncogenic signaling. Together, they highlight how transcriptional and epigenetic programs diverge across tumor contexts, contributing to inter-patient heterogeneity in LUAD.

1 day ago

Journal

TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SLC34A2 (Solute carrier family 34 member 2)

TP53 mutation • ROS1 fusion

TRUST-I: A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (clinicaltrials.gov)

P2, N=173, Active, not recruiting, Nuvation Bio Inc. | Trial completion date: Dec 2025 --> Jun 2027

7 days ago

Trial completion date

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 fusion

Ibtrozi (taletrectinib)

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=71, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

9 days ago

Enrollment closed

PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK positive • ALK fusion • ROS1 fusion • ROS1 positive

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay

Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)

13d

A Single-Arm, Single-Center, Prospective Phase II Clinical Study of Stephania Longa and Jiezai Rice Combined with Sintilimab in Advanced Driver Gene-Negative, PD-L1-Positive NSCLC Patients Who Failed First-Line Immunotherapy (ChiCTR2500114858)

P=N/A, N=29, Recruiting, Hainan General Hospital; Hainan General Hospital

13 days ago

New trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • RET fusion • ALK fusion • ROS1 fusion

Tyvyt (sintilimab)

13d

A multicenter, single-arm, open-label study to evaluate the safety and efficacy of adibelizumab combined with bevacizumab and chemotherapy as first-line treatment for patients with driver gene-negative non-squamous NSCLC with brain metastases (ChiCTR2500113887)

P4, N=30, Recruiting, Meizhou People's Hospital; Meizhou People's Hospital

13 days ago

New P4 trial

ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 fusion

Avastin (bevacizumab)

13d

non-pCR adaptive immune therapy(CTONG 2508-ADAPT-Lung) (ChiCTR2600117155)

P2, N=115, Not yet recruiting, Chengdu Third People's Hospital; Chengdu Third People's Hospital

13 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • RET fusion • ALK fusion • ROS1 fusion

Tyvyt (sintilimab)

13d

An Open-Label, Single-Center, Multi-Cohort, Phase II Study Evaluating the Safety and Efficacy of Vebreltinib-Based Combination Therapy in Previously Treated Patients with Locally Advanced or Metastatic MET-Overexpressing Non-Small Cell Lung Cancer (ChiCTR2500112942)

P2, N=52, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

13 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion

docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)

13d

A Phase II Clinical Study of JS207 (anti-PD-1/VEGF bispecific antibody) Combined with Platinum-based Doublet Chemotherapy in Subjects with Stage II-III Non-small Cell Lung Cancer (ChiCTR2500113936)

P2, N=76, Recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

13 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • RET fusion • ALK fusion • ROS1 fusion

cisplatin • carboplatin • paclitaxel • pemetrexed

13d

A First-In-Human, Multicenter, Open-Label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of KY-0301 as monotherapy or combined with other anticancer agents in Patients with advanced Solid Tumors (ChiCTR2600116103)

P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

13 days ago

New P1/2 trial

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR wild-type • MET exon 14 mutation • KRAS wild-type • RAS wild-type • ROS1 fusion • ROS1 rearrangement • MET mutation • NTRK fusion

13d

Glumetinib combined with platinum-based chemotherapy for the treatment of MET-overexpressing locally advanced or metastatic non-small cell lung cancer: A single-arm, multicenter study (ChiCTR2600117342)

P1, N=48, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

13 days ago

New P1 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • RET fusion • MET overexpression • HER-2 exon 20 insertion • ALK fusion • RET mutation • ROS1 fusion • MET mutation • NTRK fusion

carboplatin • pemetrexed • Haiyitan (gumarontinib)

13d

Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)

P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.

13 days ago

New P1 trial

BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion

izalontamab brengitecan (BL-B01D1)